You have free access to this content

Female Genital Tract Secretions and Semen Impact the Development of Microbicides for the Prevention of HIV and Other Sexually Transmitted Infections

  1. Betsy C. Herold1,2,3,
  2. Pedro M. Mesquita1,2,
  3. Rebecca P. Madan1,
  4. Marla J. Keller3,4

Article first published online: 12 DEC 2010

DOI: 10.1111/j.1600-0897.2010.00932.x

Issue

American Journal of Reproductive Immunology

American Journal of Reproductive Immunology

Special Issue: Sexual Transmission of HIV in the 21st Century

Volume 65, Issue 3, pages 325–333, March 2011

Additional Information

How to Cite

Herold, B. C., Mesquita, P. M., Madan, R. P. and Keller, M. J. (2011), Female Genital Tract Secretions and Semen Impact the Development of Microbicides for the Prevention of HIV and Other Sexually Transmitted Infections. American Journal of Reproductive Immunology, 65: 325–333. doi: 10.1111/j.1600-0897.2010.00932.x

Author Information

  1. 1

    Department of Pediatrics, Albert Einstein College of Medicine, Bronx, NY, USA

  2. 2

    Department of Microbiology-Immunology, Albert Einstein College of Medicine, Bronx, NY, USA

  3. 3

    Department of Obstetrics & Gynecology and Women’s Health, Albert Einstein College of Medicine, Bronx, NY, USA

  4. 4

    Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA

*Betsy C. Herold, MD, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Forchheimer 702, Bronx, NY 10467, USA. E-mail: betsy.herold@einstein.yu.edu

Publication History

  1. Issue published online: 7 FEB 2011
  2. Article first published online: 12 DEC 2010
  3. Submitted October 14, 2010; accepted October 18, 2010.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (242K)

References

  • 1
    UNAIDS W, AIDS epidemic update: December, 2007, UNAIDS, Geneva (2007) http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf. In.
  • 2
    Galvin SR, Cohen MS: The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004; 2:33–42.
  • 3
    Cole AM, Cole AL: Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense. Am J Reprod Immunol 2008; 59:27–34.
    Direct Link:
  • 4
    Ghosh M, Fahey JV, Shen Z, Lahey T, Cu-Uvin S, Wu Z, Mayer K, Wright PF, Kappes JC, Ochsenbauer C, Wira CR: Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS ONE 2010; 5:e11366.
  • 5
    Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM: Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol 2005; 175:7560–7567.
  • 6
    Keller MJ, Mesquita PM, Torres NM, Cho S, Shust G, Madan RP, Cohen HW, Petrie J, Ford T, Soto-Torres L, Profy AT, Herold BC: Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials. PLoS ONE 2010; 5:e8781.
  • 7
    Keller MJ, Tuyama A, Carlucci MJ, Herold BC: Topical microbicides for the prevention of genital herpes infection. J Antimicrob Chemother 2005; 55:420–423.
  • 8
    Munch J, Rucker E, Standker L, Adermann K, Goffinet C, Schindler M, Wildum S, Chinnadurai R, Rajan D, Specht A, Gimenez-Gallego G, Sanchez PC, Fowler DM, Koulov A, Kelly JW, Mothes W, Grivel JC, Margolis L, Keppler OT, Forssmann WG, Kirchhoff F: Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007; 131:1059–1071.
  • 9
    McElrath MJ: Immune responses to HIV vaccines and potential impact on control of acute HIV-1 infection. J Infect Dis 2010; 202(Suppl 2):S323–S326.
  • 10
    Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, Frankel F, Essex M, Wainberg MA: HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006; 20:F9–F13.
  • 11
    Grant PM, Aberg JA, Zolopa AR: Concerns regarding a randomized study of the timing of antiretroviral therapy in zimbabweans with AIDS and acute cryptococcal meningitis. Clin Infect Dis 2010;51:984–985; author reply 987–989.
  • 12
    Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168–1174.
  • 13
    McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, Jentsch U, Pool R, Chisembele M, Kapiga S, Mutemwa R, Vallely A, Palanee T, Sookrajh Y, Lacey CJ, Darbyshire J, Grosskurth H, Profy A, Nunn A, Hayes R, Weber J: PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010; 376:1329–1337.
  • 14
    Karim SA, Coletti A, Richardson B, Ramjee G, Hoffman I, Chirenje M, Taha T, Kapina M, Maslankowski L, Soto-Torres L: Safety and Effectiveness of Vaginal Microbicides BufferGel and 0.5% PRO 2000/5 Gel for the Prevention of HIV Infection in Women: Results of the HPTN 035 Trial In 16th Conference on Retroviruses and Opportunistic Infections Montreal, Canada, 2009.
  • 15
    Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, Pradeep BS, Krishnan AK, Alary M, Pande B, Ramjee G, Deese J, Crucitti T, Taylor D: Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008; 359:463–472.
  • 16
    Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiegne-Traore V, Uaheowitchai C, Karim SS, Masse B, Perriens J, Laga M: Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002; 360:971–977.
  • 17
    Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, Olayemi MO, Wang L, Nanda K, Rountree W: SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE 2008; 3:e1474.
  • 18
    Fichorova RN, Tucker LD, Anderson DJ: The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 184:418–428.
  • 19
    Galen BT, Martin AP, Hazrati E, Garin A, Guzman E, Wilson SS, Porter DD, Lira SA, Keller MJ, Herold BC: A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J Infect Dis 2007; 195:1332–1339.
  • 20
    Mesquita PM, Cheshenko N, Wilson SS, Mhatre M, Guzman E, Fakioglu E, Keller MJ, Herold BC: Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis 2009; 200:599–608.
  • 21
    Wilson SS, Cheshenko N, Fakioglu E, Mesquita PM, Keller MJ, Herold BC: Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety. Antivir Ther 2009; 14:1113–1124.
  • 22
    Cheshenko N, Keller MJ, MasCasullo V, Jarvis GA, Cheng H, John M, Li JH, Hogarty K, Anderson RA, Waller DP, Zaneveld LJ, Profy AT, Klotman ME, Herold BC: Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agents Chemother 2004; 48:2025–2036.
  • 23
    Neurath AR, Strick N, Li YY: Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides. BMC Infect Dis 2006; 6:150.
  • 24
    Patel S, Hazrati E, Cheshenko N, Galen B, Yang H, Guzman E, Wang R, Herold BC, Keller MJ: Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J Infect Dis 2007; 196:1394–1402.
  • 25
    Cone RA, Hoen T, Wong X, Abusuwwa R, Anderson DJ, Moench TR: Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis 2006; 6:90.
  • 26
    Van Damme L, Chandeying V, Ramjee G, Rees H, Sirivongrangson P, Laga M, Perriens J: Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers COL-1492 Phase II Study Group. AIDS 2000; 14:85–88.
  • 27
    John M, Keller MJ, Fam EH, Cheshenko N, Hogarty K, Kasowitz A, Wallenstein S, Carlucci MJ, Tuyama AC, Lu W, Klotman ME, Lehrer RI, Herold BC: Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis 2005; 192:1731–1740.
  • 28
    Keller MJ, Guzman E, Hazrati E, Kasowitz A, Cheshenko N, Wallenstein S, Cole AL, Cole AM, Profy AT, Wira CR, Hogarty K, Herold BC: PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS 2007; 21:467–476.
  • 29
    Shust GF, Cho S, Kim M, Madan RP, Guzman EM, Pollack M, Epstein J, Cohen HW, Keller MJ, Herold BC: Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception. Am J Reprod Immunol 2010; 63:110–119.
    Direct Link:
  • 30
    Iqbal SM, Ball TB, Levinson P, Maranan L, Jaoko W, Wachihi C, Pak BJ, Podust VN, Broliden K, Hirbod T, Kaul R, Plummer FA: Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS 2009; 23:1669–1677.
  • 31
    Levinson P, Kaul R, Kimani J, Ngugi E, Moses S, MacDonald KS, Broliden K, Hirbod T: Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. AIDS 2009; 23:309–317.
  • 32
    Hazrati E, Galen B, Lu W, Wang W, Ouyang Y, Keller MJ, Lehrer RI, Herold BC: Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol 2006; 177:8658–8666.
  • 33
    Sun L, Finnegan CM, Kish-Catalone T, Blumenthal R, Garzino-Demo P, La Maggiore Terra GM, Berrone S, Kleinman C, Wu Z, Abdelwahab S, Lu W, Garzino-Demo A: Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J Virol 2005; 79:14318–14329.
  • 34
    Quinones- Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, Marotta ML, Mirza M, Jiang B, Kiser P, Medvik K, Sieg SF, Weinberg A: Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 2003; 17:F39–F48.
  • 35
    Schutte BC, Mitros JP, Bartlett JA, Walters JD, Jia HP, Welsh MJ, Casavant TL, McCray Jr PB: Discovery of five conserved beta -defensin gene clusters using a computational search strategy. Proc Natl Acad Sci U S A 2002; 99:2129–2133.
  • 36
    Munk C, Wei G, Yang OO, Waring AJ, Wang W, Hong T, Lehrer RI, Landau NR, Cole AM: The theta-defensin, retrocyclin, inhibits HIV-1 entry. AIDS Res Hum Retroviruses 2003; 19:875–881.
  • 37
    Nguyen TX, Cole AM, Lehrer RI: Evolution of primate theta-defensins: a serpentine path to a sweet tooth. Peptides 2003; 24:1647–1654.
  • 38
    Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, Waring AJ, Lal RB, Lehrer RI: Activity of alpha- and theta-defensins against primary isolates of HIV-1. J Immunol 2004; 173:515–520.
  • 39
    Yasin B, Wang W, Pang M, Cheshenko N, Hong T, Waring AJ, Herold BC, Wagar EA, Lehrer RI: Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J Virol 2004; 78:5147–5156.
  • 40
    Seidel A, Ye Y, de Armas LR, Soto M, Yarosh W, Marcsisin RA, Tran D, Selsted ME, Camerini D: Cyclic and acyclic defensins inhibit human immunodeficiency virus type-1 replication by different mechanisms. PLoS ONE 2010; 5:e9737.
  • 41
    Furci L, Sironi F, Tolazzi M, Vassena L, Lusso P: Alpha-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4. Blood 2007; 109:2928–2935.
  • 42
    Feng Z, Dubyak GR, Lederman MM, Weinberg A: Cutting edge: human beta defensin 3 – a novel antagonist of the HIV-1 coreceptor CXCR4. J Immunol 2006; 177:782–786.
  • 43
    Leikina E, Delanoe-Ayari H, Melikov K, Cho MS, Chen A, Waring AJ, Wang W, Xie Y, Loo JA, Lehrer RI, Chernomordik LV: Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat Immunol 2005; 6:995–1001.
  • 44
    Cole AL, Yang OO, Warren AD, Waring AJ, Lehrer RI, Cole AM: HIV-1 adapts to a retrocyclin with cationic amino acid substitutions that reduce fusion efficiency of gp41. J Immunol 2006; 176:6900–6905.
  • 45
    Trabattoni D, Caputo SL, Maffeis G, Vichi F, Biasin M, Pierotti P, Fasano F, Saresella M, Franchini M, Ferrante P, Mazzotta F, Clerici M: Human alpha defensin in HIV-exposed but uninfected individuals. J Acquir Immune Defic Syndr 2004; 35:455–463.
  • 46
    Kuhn L, Trabattoni D, Kankasa C, Semrau K, Kasonde P, Lissoni F, Sinkala M, Ghosh M, Vwalika C, Aldrovandi GM, Thea DM, Clerici M: Alpha-defensins in the prevention of HIV transmission among breastfed infants. J Acquir Immune Defic Syndr 2005; 39:138–142.
  • 47
    Milanese M, Segat L, Arraes LC, Garzino-Demo A, Crovella S: Copy number variation of defensin genes and HIV infection in Brazilian children. J Acquir Immune Defic Syndr 2009; 50:331–333.
  • 48
    Ricci E, Malacrida S, Zanchetta M, Montagna M, Giaquinto C, De Rossi A: Role of beta-defensin-1 polymorphisms in mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2009; 51:13–19.
  • 49
    Segat L, Brandao LA, Guimaraes RL, Crovella S: Are defensin beta 1 gene polymorphisms associated with HIV infection and virus replication? AIDS 2009; 23:647–649. author reply 649-650.
  • 50
    Jana NK, Gray LR, Shugars DC: Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity. J Virol 2005; 79:6432–6440.
  • 51
    McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM: Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995; 96:456–464.
  • 52
    Wahl SM, McNeely TB, Janoff EN, Shugars D, Worley P, Tucker C, Orenstein JM: leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I. Oral Dis 1997; 3(Suppl 1):S64–S69.
  • 53
    Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hardegen N, Wild CT, Wahl SM: Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med 2004; 200:1337–1346.
  • 54
    Pillay K, Coutsoudis A, Agadzi- Naqvi AK, Kuhn L, Coovadia HM, Janoff EN: Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 183:653–656.
  • 55
    Farquhar C, VanCott TC, Mbori- Ngacha DA, Horani L, Bosire RK, Kreiss JK, Richardson BA, John- Stewart GC: Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J Infect Dis 2002; 186:1173–1176.
  • 56
    Novak RM, Donoval BA, Graham PJ, Boksa LA, Spear G, Hershow RC, Chen HY, Landay A: Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin Vaccine Immunol 2007; 14:1102–1107.
  • 57
    Mitchell CM, Balkus J, Agnew KJ, Cohn S, Luque A, Lawler R, Coombs RW, Hitti JE: Bacterial vaginosis, not HIV, is primarily responsible for increased vaginal concentrations of proinflammatory cytokines. AIDS Res Hum Retroviruses 2008; 24:667–671.
  • 58
    Anderson DJ, Williams DL, Ballagh SA, Barnhart K, Creinin MD, Newman DR, Bowman FP, Politch JA, Duerr AC, Jamieson DJ: Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: effects on markers of inflammation and innate immunity in cervicovaginal fluid. Am J Reprod Immunol 2009; 61:121–129.
    Direct Link:
  • 59
    Fakioglu E, Wilson SS, Mesquita PM, Hazrati E, Cheshenko N, Blaho JA, Herold BC: Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J Virol 2008; 82:9337–9344.
  • 60
    Ohlsson K, Bjartell A, Lilja H: Secretory leucocyte protease inhibitor in the male genital tract: PSA-induced proteolytic processing in human semen and tissue localization. J Androl 1995; 16:64–74.
  • 61
    Taggart CC, Cryan SA, Weldon S, Gibbons A, Greene CM, Kelly E, Low TB, O’ Neill SJ, McElvaney NG: Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med 2005; 202:1659–1668.
  • 62
    Wira CR, Fahey JV, Ghosh M, Patel MV, Hickey DK, Ochiel DO: Sex hormone regulation of innate immunity in the female reproductive tract: the role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens. Am J Reprod Immunol 2010; 63:544–565.
    Direct Link:
  • 63
    Schaefer TM, Fahey JV, Wright JA, Wira CR: Innate immunity in the human female reproductive tract: antiviral response of uterine epithelial cells to the TLR3 agonist poly(I:C). J Immunol 2005; 174:992–1002.
  • 64
    Schlaepfer E, Speck RF: Anti-HIV activity mediated by natural killer and CD8+ cells after toll-like receptor 7/8 triggering. PLoS ONE 2008; 3:e1999.
  • 65
    Sharkey DJ, Macpherson AM, Tremellen KP, Robertson SA: Seminal plasma differentially regulates inflammatory cytokine gene expression in human cervical and vaginal epithelial cells. Mol Hum Reprod 2007; 13:491–501.
  • 66
    Berlier W, Cremel M, Hamzeh H, Levy R, Lucht F, Bourlet T, Pozzetto B, Delezay O: Seminal plasma promotes the attraction of Langerhans cells via the secretion of CCL20 by vaginal epithelial cells: involvement in the sexual transmission of HIV. Hum Reprod 2006; 21:1135–1142.
  • 67
    Fichorova RN: Guiding the vaginal microbicide trials with biomarkers of inflammation. J Acquir Immune Defic Syndr 2004; 37(Suppl 3):S184–193.
  • 68
    Halpern V, Ogunsola F, Obunge O, Wang CH, Onyejepu N, Oduyebo O, Taylor D, McNeil L, Mehta N, Umo-Otong J, Otusanya S, Crucitti T, Abdellati S: Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS ONE 2008; 3:e3784.
  • 69
    McElrath MJ, Ballweber L, Terker A, Kreger A, Sakchalathorn P, Robinson B, Fialkow M, Lentz G, Hladik F: Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells. Antimicrob Agents Chemother 2010; 54:763–772.
  • 70
    Tao W, Richards C, Hamer D: Enhancement of HIV infection by cellulose sulfate. AIDS Res Hum Retroviruses 2008; 24:925–929.
  • 71
    Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, Boakye AY, Rountree W, Troxler A, Dominik R, Roddy R, Dorflinger L: SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS ONE 2007; 2:e1312.
  • 72
    Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, Govender S, De Kock A, Cassim N, Palanee T, Dozier G, Maguire R, Lahteenmaki P: Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1977–1987.
  • 73
    Dezzutti CS, James VN, Ramos A, Sullivan ST, Siddig A, Bush TJ, Grohskopf LA, Paxton L, Subbarao S, Hart CE: In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob Agents Chemother 2004; 48:3834–3844.
  • 74
    Olmsted SS, Dubin NH, Cone RA, Moench TR: The rate at which human sperm are immobilized and killed by mild acidity. Fertil Steril 2000; 73:687–693.
  • 75
    Connor RI: Sensitivity of non-clade B primary HIV-1 isolates to mildly acidic pH. J Acquir Immune Defic Syndr 2006; 43:499–501.
View Full Article (HTML) Get PDF (242K)